Genetic Evidence That Carbohydrate-Stimulated Insulin Secretion Leads to Obesity

Christina M. Astley,1,2,3† Jennifer N. Todd,1,2,3,4† Rany M. Salem,5 Sailaja Vedantam,1,2 Cara B. Ebbeling,1,2 Paul L. Huang,2,6 David S. Ludwig,1,2† Joel N. Hirschhorn,1,2,3,*† and Jose C. Florez2,3,4,*†

BACKGROUND: A fundamental precept of the carbohydrate–insulin model of obesity is that insulin secretion drives weight gain. However, fasting hyperinsulinemia can also be driven by obesity-induced insulin resistance. We used genetic variation to isolate and estimate the potentially causal effect of insulin secretion on body weight.

METHODS: Genetic instruments of variation in insulin secretion [assessed as insulin concentration 30 min after oral glucose (insulin-30)] were used to estimate the causal relationship between increased insulin secretion and body mass index (BMI), using bidirectional Mendelian randomization analysis of genome-wide association studies. Data sources included summary results from the largest published metaanalyses of predominantly European ancestry for insulin secretion (n = 26037) and BMI (n = 322154), as well as individual-level data from the UK Biobank (n = 138541). Data from the Cardiology and Metabolic Patient Cohort study at Massachusetts General Hospital (n = 1675) were used to validate genetic associations with insulin secretion and to test the observational association of insulin secretion and BMI.

RESULTS: Higher genetically determined insulin-30 was strongly associated with higher BMI (β = 0.098, P = 2.2 × 10⁻¹¹), consistent with a causal role in obesity. Similar positive associations were noted in sensitivity analyses using other genetic variants as instrumental variables. By contrast, higher genetically determined BMI was not associated with insulin-30.

CONCLUSIONS: Mendelian randomization analyses provide evidence for a causal relationship of glucose-stimulated insulin secretion on body weight, consistent with the carbohydrate–insulin model of obesity.

© 2017 American Association for Clinical Chemistry

1 Department of Medicine, Division of Endocrinology, Boston Children’s Hospital, Boston, MA; 2 Departments of Medicine and Pediatrics, Harvard Medical School, Boston, MA; 3 Programs in Metabolism and Medical & Population Genetics, Broad Institute, Cambridge, MA; 4 Diabetes Unit and Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA; 5 Department of Family Medicine and Public Health, University of California, San Diego, CA; 6 Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA.

† Address correspondence to: J.N.H. at 300 Longwood Ave., Boston, MA 02115. Fax 617-730-0244; e-mail joelh@broadinstitute.org. D.S.L. at 300 Longwood Ave., Boston, MA 02115. Fax 617-730-0813; e-mail david.ludwig@childrens.harvard.edu. J.C.F. at 185 Cambridge St., Boston, MA 02114. Fax 617-726-5735; e-mail jcflorez@mgh.harvard.edu.

© 2017 American Association for Clinical Chemistry
tors of an exposure of interest are used to assess the causal association between that exposure and an outcome (24).

To clarify the causal direction of relationships between 2 observed traits (e.g., insulin secretion and obesity), a bi-directional strategy using a set of genetic instruments for each trait can be used (25).

A recent Mendelian randomization analysis (26) cast doubt on the carbohydrate–insulin model, finding no evidence for a causal relationship between fasting insulin and body mass index (BMI)7. However, in the carbohydrate–insulin model, it is insulin secretion in response to carbohydrate, not fasting insulin, that influences weight gain, in part because the latter is strongly confounded by insulin resistance (5). Indeed, insulin resistance in adipose tissue protects against weight gain, as demonstrated by the fat-specific insulin receptor knock-out mouse model (27). Therefore, we selected genetic variants identified by large genome-wide association studies associated with glucose-stimulated insulin secretion, not fasting insulin, to more appropriately test the carbohydrate–insulin model.

Methods

STUDY DESIGN

Mendelian randomization is an analytic method that leverages the random assignment of genetic variants at conception to infer causal effects. Because genetic variants are randomly assorted during meiosis, this approach can be understood as analogous to an instrumental variable analysis of a randomized trial with nonadherence, in which exposure groups are defined by genotype rather than by an assigned intervention. One limitation of Mendelian randomization is difficulty in distinguishing the directionality of causation because genetic variants could have their primary influence on either trait. A bidirectional strategy (Fig. 1) can be used in this situation, using separate sets of instruments for each trait to perform analyses in both directions (25). This strategy has been used by others to demonstrate that obesity is causal for traits such as high C-reactive protein (28) and high uric acid (29). We used bidirectional Mendelian randomization to assess the causal relationship between glucose-stimulated insulin secretion [as quantified by insulin levels 30 min after oral glucose (insulin-30) and obesity (as quantified by BMI)].

We used publicly available, summary-level data from large-scale genome-wide association studies to identify single-nucleotide polymorphisms (SNPs) that would serve as genetic instruments for each trait (insulin-30 and BMI), and individual-level data to validate the associa-
tion of the instruments with the intermediate phenotype (Fig. 2). The analyses were performed on summary-level data; the use of summary-level data enables more powerful analyses with a larger sample size and is comparable with individual-level analysis for larger sample sizes (30, 31).

**DATA SOURCES AND STUDY SUBJECTS**

We used summary-level data from the MetaAnalysis of Glucose- and Insulin-related traits Consortium (MAGIC) and the Genetic Investigation of ANthropometric Traits (GIANT) consortium for glucose-stimulated insulin secretion and BMI, respectively (32, 33). MAGIC included up to 26,037 nondiabetic individuals of European ancestry who underwent oral glucose tolerance testing and genome-wide, CardioMetabochip (Illumina), or specific targeted genotyping of candidate loci (32). GIANT included up to 322,154 individuals of European ancestry from population-based and case–control studies with anthropometric data and either genome-wide or CardioMetabochip genotyping (33). Contributing studies to each consortium received approval from their respective institutional review boards.

To validate SNP–trait association measures for variants in genetic risk scores, we used individual-level data from the UK Biobank to validate SNP–trait association measures for variants in the BMI genetic risk score and to perform the forward analysis (the test of insulin-30 as causal for BMI). Of >500,000 participants who were recruited from 2006 through 2010, 138,541 participants had available genetic data, self-identified as British, Irish, or other white background, passed quality control (omitting samples with poor heterozygosity, reported and genetic sex mismatch, first principal component equal to 0, principal component >4 SDs from the mean, or information score <0.3), and had the required covariates [height (cm) by Seca 202 device, weight (kg), BMI, age, sex] measured at
the baseline assessment. Individuals were not censored for current or future cardiometabolic risk factors. UK Biobank obtained approval from its governing Research Ethics Committee. Analysis of the UK Biobank data was approved by the Broad Institute Institutional Review Board.

**INSTRUMENT SELECTION AND VALIDATION**

To assess insulin secretion, we used as instrumental variables genetic variants associated with insulin-30 \( (34, 35) \). Insulin-30 was chosen because it has been shown to be an effect modifier of the relationship between high glycemic load carbohydrates and weight gain in translational research, observational studies, and clinical trials \( (7–10, 15) \).

Because analysis by the MAGIC consortium identified only 3 variants associated with insulin-30 at genome-wide significance \( (P \leq 5 \times 10^{-8}) \), see Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol64/issue1 \( (32) \), we used 2 strategies to expand the set of genetic instruments. First, we grew our list to include variants with subgenome-wide \( (P \leq 5 \times 10^{-5}) \) association with insulin-30 (see Table 1 in the online Data Supplement). Second, we included variants associated at genome-wide significance for 5 additional glucose-stimulated insulin secretion (GSIS) traits: corrected insulin response, corrected insulin response adjusted for insulin sensitivity index, change in insulin at 30 min from baseline, disposition index, and insulin-30 adjusted for BMI (see Table 1 in the online Data Supplement). This selection scheme resulted in 3 insulin-30 genetic instrument sets: insulin-30-stringent (3 variants), insulin-30-relaxed (40 variants), and GSIS-stringent (7 variants).

For BMI, we selected the 97 variants reported by the GIANT consortium to be associated with BMI at a genome-wide level of significance \( (P \leq 5 \times 10^{-8}) \) (see Table 2 of the online Data Supplement). One BMI variant \( (rs2033529) \) was not present in the imputed UK Biobank data and did not have a suitable proxy SNP; therefore, it was omitted from the analysis in this cohort.

Genetic risk scores (GRSs) for each trait were created using weights equal to the effect estimates from the MAGIC association study \( (32) \) or GIANT association study \( (33) \) (see Table 2 of the online Data Supplement). One BMI variant \( (rs2033529) \) was not present in the imputed UK Biobank data and did not have a suitable proxy SNP; therefore, it was omitted from the analysis in this cohort.

Genetic risk scores (GRSs) for each trait were created using weights equal to the effect estimates from the MAGIC association study \( (32) \) or GIANT association study \( (33) \). We validated our instrument sets by estimating the variance explained by the GRSs for each trait in cohorts that were independent from those used to estimate the weights. The GRSs for insulin-30 were validated in CAMP-MGH, and the GRS for BMI was validated in both CAMP-MGH and UK Biobank. Variance explained by the GRSs in the validation cohorts was compared with the estimated variance explained from the association study (calculated as the square of the effect estimate multiplied by the variance of a binomial random variable with probability of success equal to the minor allele frequency). For the UK Biobank analysis, GRS was normalized by the mean effect size of all instruments, such that the linear regression coefficient reflected the mean per allele effect.

**STATISTICAL ANALYSIS**

In the CAMP-MGH cohort, we carried out association analysis on insulin-30 after natural log transformation with adjustment for age and sex, as in the MAGIC analysis \( (32) \). We tested association for each individual SNP in the insulin-30 instrument set under an additive genetic model. We validated the insulin-30 and BMI GRSs as predictors of transformed insulin-30 and BMI, respectively, using linear regression.

In the UK Biobank group, we carried out association analysis on BMI after regression on covariates (age, age squared, and the first 10 principal components) and inverse normalized transformation of residuals, stratified by sex, as in the GIANT analysis \( (33) \). Genome-wide association was performed under an additive genetic model, and effect estimates for males and females were combined by metaanalysis. We metaanalyzed UK Biobank effect estimates for males and females with GIANT summary statistics. We modeled covariate-adjusted BMI (age, age squared, sex) in the UK Biobank as a continuous outcome with linear regression using the weighted insulin-30 and BMI GRSs as predictors.

We estimated the causal effect of an exposure on an outcome by calculating the ratio of SNP-outcome to SNP-exposure effect estimates using the Genetics ToolboX package (https://CRAN.R-project.org/package=gtx). This approach is equivalent to an inverse variance weighted fixed-effects metaanalysis model of ratio estimates across all variants in the instrumental variable set \( (31) \). We used bidirectional Mendelian randomization to estimate the effect of insulin-30 on BMI (Fig. 1A) and the effect of BMI on insulin-30 (Fig. 1B). To create effect estimates that were more clinically interpretable, we scaled insulin-30 effect estimates from the MAGIC association study by the SD of natural log insulin-30 estimated in CAMP-MGH (i.e., SNP–insulin-30 association divided by 0.66). BMI effect estimates have similar interpretation, as BMI was inverse normalized transformed in the GIANT association study.

To assess for violations of Mendelian randomization assumptions, we tested for heterogeneity and directional pleiotropy under the Instrument Strength Independent of Direct Effect (or InSIDE) assumption, according the method of Bowden et al. \( (36) \). We also performed sensitivity analyses by omitting instrument outliers and comparing results with the simple median estimator \( (37) \).
Results

VALIDATION OF INSULIN-30 AND BMI INSTRUMENT SETS
We assembled 3 different lists of genetic variants that have been associated at different levels of stringency with measures of GSIS; we named these insulin-30-stringent (3 variants), insulin-30-relaxed (40 variants), and GSIS-stringent (7 variants; see Fig. 2A and Methods for details). To validate these sets of genetic variants for use as instruments in Mendelian randomization, we examined their effects on insulin-30 in the independent CAMP-MGH cohort (Table 1). In this cohort, the insulin-30-stringent, insulin-30-relaxed, and GSIS-stringent instrument sets accounted for 0.9%, 0.05%, and 1.1% of the phenotypic variance in insulin-30, respectively, compared with 0.6%, 9.0%, and 0.7% in the MAGIC consortium. Individual SNPs were directionally consistent within the primary instrument set (insulin-30 stringent) and for the majority (6 of 7) of variants in the GSIS-stringent set (see Table 3 in the online Data Supplement). In contrast, only 26 of 40 of the insulin-30-relaxed set were directionally consistent with the published genome-wide association study effects (see Table 3 in the online Data Supplement). Thus, relaxing the significance threshold appeared to increase the number of potential instruments at the expense of including false-positive findings, as demonstrated by both the more modest directional consistency and the difference in variance explained in the discovery and validation data sets. We also validated the published set of 97 BMI-associated variants (Fig. 2B); these explained 1.0% of the variation in BMI in the CAMP-MGH group and 1.8% of variation in the UK Biobank cohort (described in Table 1), compared with 2.7% in the GIANT consortium. Nearly all BMI instruments (95 of 96) were directionally consistent in UK Biobank; 1 BMI instrument (rs11126666) was not statistically associated with BMI (P = 0.89).

OBSERVATIONAL ASSOCIATION OF INSULIN-30 WITH BMI
As in other correlational epidemiological studies, we found a positive correlation of BMI with insulin-30 in the CAMP-MGH cohort (r = 0.35, P < 0.0001). BMI was also correlated with baseline insulin, age, and sex (Table 2). Higher BMI remained associated with higher insulin-30 levels (P < 0.0001) even when adjusting for age and sex in a multivariate model.

GRS INSULIN-30 ASSOCIATED WITH HIGHER BMI
Using linear regression, the insulin-30-stringent GRS (β = 0.095 kg/m² per insulin-30 increasing allele, P = 1.1 × 10⁻¹²) was associated with higher BMI in the UK Biobank cohort. Neither the alternative insulin secretion GRS including GSIS-stringent GRS (P = 0.26) nor the insulin-30-relaxed GRS (P = 0.18) was found statistically associated with BMI. The association of higher BMI being found with higher genetic risk for early insulin secretion suggests that factors downstream of the insulin-30 genetic instruments may promote obesity.

GENETICALLY DETERMINED INSULIN-30 ASSOCIATED WITH HIGHER BMI
To further test for a causal role for insulin secretion in obesity, we used the insulin-30 instrumental sets in a Mendelian randomization analysis (Figs. 1A and 2A). Higher genetically determined insulin-30 was associated with higher genetically determined BMI using all 3 of the insulin secretion instrument sets in the GIANT data set (insulin-30-stringent β = 0.095, P = 1.8 × 10⁻¹²; GSIS-stringent β = 0.055, P = 8.5 × 10⁻⁷; insulin-30-relaxed β = 0.01, P = 0.02) (Fig. 3). The insulin-30-stringent instrument set, with instruments selected based on the narrowest GSIS trait definition and most stringent statistical significance threshold, yielded the highest effect estimates for insulin-30 on BMI. The broader (GSIS-stringent) and less stringent (insulin-30-relaxed) instrument sets produced progressively smaller effect estimates for insulin-30 on BMI.

Mendelian randomization effect estimates using the UK Biobank group (insulin-30-stringent β = 0.104, P = 1.3 × 10⁻¹⁰), a population-based cohort independent from the data used to identify insulin secretion in-
Instruments, or UK Biobank metaanalyzed with GIANT (insulin-30-stringent β = 0.098, P = 2.2 × 10^{-21}) were consistent with those obtained using GIANT alone. We obtained similar effect estimates and trends for the other 2 insulin-30 instrument sets using the UK Biobank cohort and metaanalyzed data (see Table 4 in the online Data Supplement). These positive effect sizes are consistent with a causal role for insulin-30 on body weight, with increased early insulin secretion leading to higher BMI.

We performed 2 analyses to test the robustness of these results. We noted substantial heterogeneity in effect estimates for the variants in each of the 3 instruments related to insulin secretion (heterogeneity P values ranging from 7.3 × 10^{-23} to 2.2 × 10^{-7}). Therefore, we considered the possibility that the results were driven by a subset of SNPs within each instrument. We omitted the variant that individually produced the strongest effect estimate (QPCTL/GIPR, rs2287019) from the insulin-30-stringent instrument, and found that heterogeneity was eliminated whereas the 2-instrument set was still statistically significantly associated with BMI, albeit with an attenuated effect size (β = 0.045, P = 4.2 × 10^{-4}, heterogeneity P = 0.34) (see Fig. 1 in the online Data Supplement). Thus, the results are robust to removal of individual variants with outlier effect sizes. The simple median estimator—the median estimate of the individual SNP-outcome to SNP-exposure ratios—was positive for the insulin-30-stringent (β = 0.059) and GSIS-stringent (β = 0.016) instrument sets. The insulin-30-relaxed instrument simple median estimator was also positive but close to zero (β = 0.00017).

We tested for pleiotropy, a known confounder of Mendelian randomization analyses, in which a subset of the variants in the instrument can be independently associated with both the exposure (insulin-30) and the outcome (BMI). The Egger test, which tests for directional pleiotropy, was not statistically significant for any of the instrument sets (Egger intercept insulin-30-stringent P = 0.53, GSIS-stringent P = 0.27, insulin-30-relaxed P = 0.92).

**GENETICALLY DETERMINED BMI NOT ASSOCIATED WITH HIGHER INSULIN-30**

Finally, we used bidirectional Mendelian randomization to further examine the directionality of the relationship between insulin-30 and BMI (Fig. 1B). Instead of using

---

Fig. 3. Mendelian randomization effect estimates. Estimates of higher insulin concentration 30 min after oral glucose on BMI, using 3 different instrument sets (insulin-30-stringent, insulin-30-relaxed, and GSIS-stringent).

---

*Human genes: QPCTL, glutaminyl-peptide cyclotransferase like; GIPR, gastric inhibitory polypeptide receptor.*
the combined insulin-30 associated variants as an instrument, we performed Mendelian randomization in the reverse direction, using 97 loci known to be associated with BMI in GIANT (33) as an instrument set (Fig. 2B). We tested this set for association with early insulin secretion in the MAGIC data. We found no evidence of a reverse causal effect for BMI on insulin-30 (β = 0.115, P = 0.43, heterogeneity P = 0.13).

Discussion

Our genetic-based analyses support a causal relationship of genetically determined glucose-stimulated insulin secretion with obesity. Genetic predisposition to higher levels of glucose-stimulated insulin secretion predicted higher adult BMI, whereas the reverse hypothesis—that genetic predisposition to obesity would predict higher levels of glucose-stimulated insulin secretion—did not hold true.

These results lead to 2 conclusions. First, it appears that a lifetime of high glucose-stimulated insulin secretion, likely in conjunction with typical diets consumed by the individuals in these cohorts, is obesogenic. An increase in log insulin-30 by 1 SD was associated with a 0.1-SD increase in covariate-adjusted BMI. This effect size roughly translates to a 160- to 180-cm person with below average insulin secretion (−1 SD) weighing 2.5 to 3.1 kg less than the same person with above-average insulin secretion (+1 SD). These findings lend additional support to the carbohydrate–insulin model of weight regulation, which postulates that diets high in glycemic load promote weight gain through the anabolic effects of increased insulin secretion.

Second, our findings suggest a role for “precision medicine” in dietary interventions. Two clinical trials indicate that individuals with high baseline insulin-30 have greater weight loss on low glycemic load diets than those with low insulin-30 (10, 15). Consistent with recent conjecture, consideration of obesity subtypes might lead to more effective long-term treatment. Although measurement of insulin-30 with oral glucose tolerance testing may not always be feasible, genetic testing for insulin secretion-associated polymorphisms may still be of value, as the GRS for insulin-30 was associated with insulin-30 and BMI.

Our study has potential limitations, as the ability to leverage genetic instruments to assess causal relationships with Mendelian randomization relies on 2 principles (Fig. 1): the strength of the instrument relative to other sources of variation in the exposure (assumption 1), and the absence of instrument–outcome associations not mediated by the exposure–outcome causal effect of interest (assumptions 2 and 3). The insulin-30 and BMI genetic instruments explained a relatively small fraction (approximately 1%–3%) of variation in the respective exposures. Large sample sizes will enhance power when using an instrument that explains only a small fraction of total variation in traits. An F-statistic >10 has been typically used as a threshold for a strong instrument relative to sample size in the Mendelian randomization literature (38). Estimated F-statistics based on the variance explained and the sample size in UK Biobank are >1000, indicating that these instruments are of sufficient strength to be used to estimate the exposure–outcome association.

As the biological mechanisms are unknown for many of the genetic variants used in our analyses, we cannot know for certain that the second principle of Mendelian randomization, the absence of off-target instrument–outcome associations (assumptions 2 and 3 in Fig. 1) such as pleiotropy, holds true. In the absence of knowledge of gene–trait biology, we used 2 statistical techniques, the Egger test and the removal of heterogeneous instruments, to test these assumptions. The Egger test has been developed to assess for violations of a special case termed directional pleiotropy (under the InSIDE assumption). The Egger test was not statistically significant for any of the analyses, although this test is not well-powered and may not be valid in the context of substantial heterogeneity and/or violations of the InSIDE assumption (36). Tests for heterogeneity were statistically significant for all the instrument sets, which may be a marker of the true underlying biology, sample size for the testing data, or violation of the assumption for Mendelian randomization. Our results were robust to removal of the variants that contributed to the heterogeneity.

By studying genetic associations with >1 trait, genetic epidemiology studies can elucidate underlying biology of genetic variants. The SNP rs2287019, which is most proximal to the QPCTL and GIPR genes, stands out in our analysis as both a strong instrument for insulin-30 and a strong predictor of BMI. It was significant at a genome-wide level for both traits (32, 33), as would be expected if there were a true causal effect of insulin secretion on BMI, or pleiotropy. There are good reasons that this instrument likely acts, at least in part, through insulin-30. GIPR encodes the receptor for the glucose-dependent insulinotropic peptide, an incretin hormone produced by the K cells in the intestines (39). The glucose-dependent insulinotropic peptide mediates early insulin secretion after enteral nutrition, particularly carbohydrate intake (40). Thus, the known biology suggests that this variant is a particularly relevant instrument for testing the effects of glucose-mediated insulin secretion. Effect estimates for this instrument strongly support the hypothesis that genetically determined insulin-30 has a large effect on BMI, and Mendelian randomization effect estimates are higher for this instrument than that for any other instrument. Therefore, this instrument is particularly plausible and lends strong support to the
carbohydrate–insulin model. Another implication of this finding is that individuals with variation in the glucose-dependent insulinotropic peptide receptor that increases both BMI and insulin-30 may be especially sensitive to the effects of a high glycemic load diet.

In summary, we found that genetic predisposition to higher glucose-stimulated insulin secretion was associated with higher BMI. This finding supports the carbohydrate–insulin model of obesity. These results underscore the need for adequately powered clinical trials and mechanistic studies of sufficient duration to explore how individuals with low vs high insulin secretion status respond to diets differing in glycemic load.

Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.

References